(Q40076328)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6085531%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

review article

1 reference

title

The pharmacology of prodrugs of 5-fluorouracil and 1-beta-D-arabinofuranosylcytosine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6085531%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

The Pharmacology of Prodrugs of 5-Fluorouracil and 1-β-D-Arabinofuranosylcytosine (English)

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

1 reference

A. F. Hadfield

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6085531

1 August 2023

A. C. Sartorelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6085531

1 August 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6085531

1 August 2023

publication date

1 January 1984

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6085531%20AND%20SRC:MED&resulttype=core&format=json

Advances in pharmacology and chemotherapy

26 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6085531%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6085531%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

page(s)

21-67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6085531%20AND%20SRC:MED&resulttype=core&format=json

Chemical Aspects of Selective Toxicity

26 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical tr

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Stimulation of secretion of epidermal growth factor and amylase of cyclocytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Phase I-II study of ftorafur and methyl-ccnu in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Results of treatment of malignant tumors with ftorafur

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Tumor inhibitory effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Therapeutic effect of Leo 1031, an alkylating corticosteroid ester, in lymphoproliferative disorders. I. chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Experimental and clinical studies on nucleoside analogs as antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Mechanism of the Cardiovascular Actions of Cyclocytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Phase ii evaluation of ftorafur in previously untreated colorectal cancer: A southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Augmentation by thymidine of the incorporation and distribution of 5-fluorouracil in ribosomal RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Antitumor and antileukemic effects of some steroids and other biologically interesting compounds containing an alkylating agent

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Editorial: Large-bowel cancer-The current status of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

The chemotherapy of urologic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Acute myelocytic leukemia in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Comparative effects of ftorafur and 5-fluorouracil on DNA synthesis in rat small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Cure of Mice bearing Advanced Plasma Cell Tumours with Aniline Mustard : the Relationship between Glucuronidase Activity and Tumour Sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Metabolism of aniline mustard [N,N-di-(2-Chloroethyl)-aniline]

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Towards selectivity? approaches to the design of new anti-tumour agents—I

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Biochemical and pharmacological studies with 1-beta-D-arabinofuranosylcytosine in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Cytosine arabinoside (NSC 63878) toxicity and antitumor acitivity in human solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Nucleosides. XXXIX. 2'-deoxy-2'-fluorocytidine, 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine, and related derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Analogs of 1-beta-D-arabinofuranosylcytosine. Studies on mechanisms of action in Burkitt's cell culture and mouse leukemia, and in vitro deamination studies

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Treatment of Advanced Carcinoma of the Prostate with Estramustine Phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Nucleosides. XCI. Some chemical properties of the antileukemic agent 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Nucleosides. XXIX. 1-β-D-Arabinofuranosyl-5-fluorocytosine and Related Arabino Nucleosides1

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

The Metabolism of Ftorafur in the Beagle Dog and Rhesus Monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Studies on the Fate of 1-(2-Tetrahydrofuryl)-5-fluorouracil (FT-207), a Carcinostatic Agent. III. Absorption, Distribution, Excretion and Metabolism after Rectal Administration of FT-207

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Autoradiographic Analyses of the Cytokinetic Effects of Bleomycin on the Mouse Tumor2

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Nucleic acids. 11. Synthesis of 5'-esters of 1-.beta.-D-arabinofuranosylcytosine possessing antileukemic and immunosuppressive activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Reactions of 2-acyloxyisobutyryl halides with nucleosides. 6. Synthesis and biological evaluation of some 3'-acyl derivatives of 2,2'-anhydro-1-(.beta.-D-arabinofuranosyl)cytosine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Reactions of 2-acyloxyisobutyryl halides with nucleosides. 7. Synthesis and biological evaluation of some 2,2'-anhydro-1-(3',5'-di-O-acyl-.beta.-D-arabinofuranosyl)cytosine hydrochlorides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Reactions of 2-acyloxyisobutyryl halides with nucleosides. 8. Synthesis and biological evaluation of some 3'-acyl and 3',5'-diacyl derivatives of 1-.beta.-D-arabinofuranosylcytosine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

1 reference

7 January 2021

Studies on the toxicity and antitumour activity of prednimustine, a prednisolone ester of chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Biochemical studies of a new antitumor agent, O2,2′-cyclocytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-.beta.-D-arabinofuranosylcytosine conjugates of prednisolone and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Synthesis and antitumor activity of 1-β-D-arabinofuranosylcytosine conjugates of cortisol and cortisone

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Synthesis and antitumor activity of 1-β-D-arabinofuranosylcytosine-5′-diphosphate-prednisolone and -cortisol

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Ftorafur, adriamycin, cyclophosphamide and bcg in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Specific inhibition of DNA synthesis by cyclocytidine.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Autoradiographic study on the distribution of cyclocytidine in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil against L1210 leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Antitumor activity of metabolites of 1-hexylcarbamoyl-5-fluorouracil and related compounds against L1210 leukemia in vivo and L5178Y lymphoma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil after oral administration in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Treatment of Advanced Prostatic Carcinoma with Estramustine Phosphate (Estracyt®)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Studies on the fate of 5-fluoro-1,3-bis(tetrahydro-2-furanyl)-2,4-pyrimidinedione (FD-1), a new antitumor agent. I. Absorption, distribution, excretion and metabolism of FD-1 administered orally to rats (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Fluorinated pyrimidines. XXIX. Syntheses of 2',3'-dehydro-5-fluoro-2'-deoxyuridine and 2',3'-dideoxy-5-fluorouridine.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

On the reaction of vilsmeier-haack reagent with nucleoside: a convenient synthesis of 2,2′-cyclocytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Studies on phenolic steroids in human subjects. XIV. Fate of a nitrogen mustard of estradiol-17beta

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a new antitumour agent, in rats, rabbits and dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Studies on biologically active nucleosides and nucleotides. 5. Synthesis and antitumor activity of some 2,2'-anhydro-1-(3',5'-di-O-acyl-beta-D-arabinofuranosyl)cytosine salts and 2,2'-anhydro-1-(3'-O-acyl-beta-D-arabinofuranoxyl)cytosine 5'-phosphat

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Determination of two new metabolites of 1-hexylcarbamoyl-5-fluorouracil in biomedical specimens by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

1-Hexylcarbamoyl-5-fluorouracil (HCFU)--a masked 5-fluorinated pyrimidine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Physiological distribution of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine (AAFC) in man

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Drug latentiation. Synthesis and preliminary evaluation of testosterone derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Estramustine phosphate in the treatment of advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Synthesis and biological activities of ftorafur metabolites. 3'- and 4'-Hydroxyftorafur

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Metabolism and Disposition of Baker's Antifolate (NSC-139105), Ftorafur (NSC-148958), and Dichlorallyl Lawsone (NSC-126771) in Man

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

The synthesis, characterization, and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine-5'-diphosphate-L-1,2-dipalmitin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Structure of two hydroxylated metabolites of ftorafur

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Synthesis and antitumor and antiviral activities of 1-.beta.-D-arabinofuranosyl-2-amino-1,4(2H)-iminopyrimidine, and its derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Extended Therapy of Stage D Carcinoma of the Prostate with Oral Estramustine Phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Therapeutic effect of Leo 1031, an alkylating corticosteroid ester; in lymphoproliferative disorders. II. Lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Biochemical and pharmacologic studies with 1-β-d-arabinofuranosylcytosine 5′-adamantoate (NSC-117614), a depot form of cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Pharmacokinetics Molecular Modification: Implications in Drug Design Evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

1 reference

7 January 2021

A Phospholipid Derivative of Cytosine Arabinoside and Its Conversion to Phosphatidylinositol by Animal Tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Inhibition of Cyclocytidine-Induced Enlargement of Parotid and Heart by Propranolol or Sympathectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

On the mechanism of storage of anhydro-araC.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Phase I study of ftorafur, an analog of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Prodrugs and site-specific drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Chemotherapy of cell-line-derived human colon carcinomas in mice immunosuppressed with antithymocyte serum

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Cytotoxic liponucleotide analogs. I. Chemical synthesis of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Cytotoxic liponucleotide analogs. II. Antitumor activity of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Steroid-nucleosides possible novel agents for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Ftorafur: A self-limiting source of 5-fluorouracil?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Nucleic acids. 14. ara-Cytidine acylates. Use of drug design predictors in structure-activity relation correlation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Nucleic acids. 16. Orally active derivatives of ara-cytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

DRUG-INDUCED REGRESSION OF LARGE PLASMA CELL TUMOURS

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Cure of Mice Bearing Advanced Plasma Cell Tumours With Aniline Mustard

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

A phase II trial of ftorafur. Adriamycin and mitomycin-C (FAM II) in advanced gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-5-fluorouracil into the R and S isomers and examination of the biological activities of the isomers

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Studies on antitumor agents. 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

Therapeutic trial of aniline mustard in patients with advanced cancer. Comparison of therapeutic response with cytochemical assessment of tumor cell beta-glucuronidase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960264-1

7 January 2021

1

66

1307

Abele

1982

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

3

60

281

Alberto

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

7

36

2726

Aoshima

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

8

37

2481

Aoshima

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

9

40

3333

Armstrong

1980

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

10

39

4289

Au

1979

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

11

40

2814

Au

1980

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

12

63

343

Au

1979

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

14

60

875

Basler

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

17

38

3867

Benvenuto

1978

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

18

39

3199

Benvenuto

1979

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

19

31

66

Bertalanffy

1971

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

24

26

370

Burchenal

1966

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

27

61

437

Burgess

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

29

61

463

Buroker

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

30

61

1579

Buroker

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

31

62

689

Buroker

1978

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

41

61

617

Chou

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

Drug Metabolism and Disposition

1 August 2023

45

3

303

Cohen

1975

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

52

61

1725

Cullinan

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

54

37

2771

deKernion

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

55

61

1581

Diggs

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

58

61

909

Double

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

60

61

805

El Dareer

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

61

63

1331

Finklestein

1979

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

62

39

5155

Forsgren

1979

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

67

32

2269

Fox

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

68

29

1325

Frei

1969

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

78

36

33

Fujimoto

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

83

28

2061

Furth

1968

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

84

60

1347

Garibjanian

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

87

17

224

Grubb

1975

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

88

61

1495

Hall

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

95

63

1389

Harrison

1979

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

98

60

1663

Herman

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

Proceedings of the USSR Academy of Sciences

1 August 2023

99

176

332

Hiller

1967

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

104

33

2816

Ho

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

Drug Metabolism and Disposition

1 August 2023

105

1

752

Ho

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

107

61

717

Ho

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

108

37

1640

Ho

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

Drug Metabolism and Disposition

1 August 2023

109

3

309

Ho

1975

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

Clinical pharmacology of O2,2'-cyclocytidine

1 August 2023

110

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

118

35

1301

Horwitz

1975

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

131

63

1895

Iigo

1979

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

138

62

1089

Issell

1978

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

139

60

1335

Johnson

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

142

66

201

Karakousis

1982

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

144

26

166

Karon

1966

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

145

60

277

Kaufman

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

148

62

463

Kemeny

1978

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

152

39

3129

Khwaja

1979

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

154

25

698

Kim

1965

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

155

26

1661

Kim

1966

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

156

34

1031

Kirdani

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

158

40

107

Kirkwood

1980

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

166

64

861

Koyama

1980

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

168

35

2453

Kreis

1975

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

172

29

1790

Lenaz

1969

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

174

62

1259

Lippman

1978

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

179

62

469

McKelvey

1978

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

Quantitative determination of 1,3-bis(tetrahydro-2- furanyl)-5-fluoro-2,4-pyrimidinedione and its metabolites in plasma by high-pressure liquid chromatography and gas chromatography-mass fragmentography

1 August 2023

181

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

184

63

1913

Miale

1979

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

186

60

215

Minow

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

189

61

307

Mittelman

1977

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

The Use of Estramustine and Prednimustine Versus Prednimustine Alone in Advanced Metastatic Prostatic Cancer Patients Who Have Received Prior Irradiation

1 August 2023

194

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

197

30

1047

Neil

1970

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

202

62

455

O'Bryan

1978

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

207

18

730

Rich

1958

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

Unexpected Adrenergic Effects of the Antitumor Agent, Cyclocytidine, on Rat Salivary Glands

1 August 2023

212

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

233

39

1063

Tsuruo

1979

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

234

40

4758

Tsuruo

1980

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

238

28

2529

Umeda

1968

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

240

36

1821

Valdivieso

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

242

62

1251

van Lier

1978

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

245

32

1489

Verbin

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

246

33

1265

Wang

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

251

35

3014

Wilkinson

1975

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

256

38

210

Wu

1978

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60264-1

1 August 2023

Identifiers

0 references

1 reference